Nebenwirkungen · Comirnaty
Comirnaty KP.2 30 micrograms/dose dispersion for injection Comirnaty KP.2 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty KP.2 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 76
HOS-148992 · Präparat HOS-099980
Children 5 to 11 years of age (i.e. 5 to less than 12 years of age) – after booster dose In a subset from Study 3, a total of 2 408 children 5 to 11 years of age received a booster dose of Comirnaty 10 mcg at least 5 months (range of 5.3 to 19.4 months) after completing the primary series. The analysis of the Study 3 Phase 2/3 subset is based on data up to the cut-off date of 28 February 2023 (median follow-up time of 6.4 months).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage f37b795f1d6c5e9f13f34eb955844c99768bf4cadbee31501923a58f6d53a6b4 · Zeichen 2027–2461 im Abschnitt